Diagnosed in thousands of American men each year, testicular cancer has proven highly sensitive to current treatment regimens. Host Dr. Mark Nolan Hill evaluates the most common therapies for testicular cancer with Dr. Craig Nichols, medical director of lymphoma and testicular cancer research at Providence Portland Medical Center in Portland, Ore., and an internationally respected expert on testicular cancer. Are there significant side effects to the present therapies? Further, keeping in mind the possibility of a recurrent disease, and the accordant need for proper follow-up measures, Dr. Nichols evaluates strategies for coordinating care between medical oncologists and primary care physicians.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Testicular Cancer: Raising Already Lofty Cure Rates
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
Diagnosed in thousands of American men each year, testicular cancer has proven highly sensitive to current treatment regimens. Host Dr. Mark Nolan Hill evaluates the most common therapies for testicular cancer with Dr. Craig Nichols, medical director of lymphoma and testicular cancer research at Providence Portland Medical Center in Portland, Ore., and an internationally respected expert on testicular cancer. Are there significant side effects to the present therapies? Further, keeping in mind the possibility of a recurrent disease, and the accordant need for proper follow-up measures, Dr. Nichols evaluates strategies for coordinating care between medical oncologists and primary care physicians.
Presenters
Facebook Comments